In Depth 19 Jan 2022 Glycans Hit the Sweet Spot in Diagnostics …The human genome comprises about 25,000 protein-encoding genes. In comparison, the human glycome comprises millions of different kinds of possible glycans. Glycans are composed of simple sugars linked together to… January 19, 2022 - 5 minutesmins - By Sachin Rawat Share WhatsApp Twitter Linkedin Email
News and Trends 1 Mar 2018 Doudna and Charpentier Get Second CRISPR Patent in Europe …to inactivate its DNA-cutting function. “It becomes a targeting vehicle, so then you can hook almost anything you want to deliver it to anywhere within the genome,” Eric Rhodes told… March 1, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Feb 2018 ProQR Tackles Blindness Caused by a Rare Genetic Disease …changes to be made to the genome. The potential of the treatment has been highlighted by the FDA awarding it with Orphan Drug Designation. Usher syndrome type 2a is caused… February 13, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jan 2023 Researchers discover new type of CRISPR gene scissors …foreign genome, such as the DNA of a virus, for targeted cleavage. The CRISPR-associated (Cas) nuclease directed by a crRNA can cut its target like a pair of scissors: a… January 5, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Mar 2023 Beyond Biotech podcast 38: Hello Tomorrow Global Summit …epigenetics and 3D genome structures through data and machine learning to design high precision gene-editing systems. The company’s platform enables the design of appropriate gene editing apparatus. It prevents editing… March 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2024 Top biotech deals of November 2024 …part of the CRISPR nuclease family – to develop more efficient gene and cell therapies. As part of the deal, Integra will use the genome editor Cas12l in its gene-writing… December 12, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 Mar 2024 Eight CAR-T cell therapy companies you should know about …market The human genome mapping in 2003 laid the foundation for immunotherapy research. Soon enough, scientists in the U.S. began to actualize the idea behind CAR-T therapies, and then, the… March 21, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 6 Nov 2018 Potential HIV Treatment Shows Early Stage Promise …the enzyme that HIV uses to insert viral DNA into the host cell’s genome. Integrase then inserts too much viral DNA into the cell, blowing the virus’s cover and making… November 6, 2018 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 Jan 2017 The Shiniest Golden Vertex? 15 Great Biotechs in Cambridge …services interact with the Biotech ecosystem in Cambridge and in the UK. Focused on genome-based medicine, Congenica was founded in 2013 and based on research from the Wellcome Trust Sanger… January 30, 2017 - 8 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2022 Tevogen Bio to investigate T cell therapy in long Covid …expanded in the lab and recognize proteins from across the entire SARS-CoV-2 genome, not just the spike protein. In July 2022, TVGN-489 completed POC clinical trial enrollment with zero treatment-related… November 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 11 Aug 2022 Biosecurity is synthetic biology’s most crucial ally …measures. Upskilling genome foundries and equipping them for rapid responses in the event of biosecurity threats, as we have seen in the Covid response, is also a way of containing… August 11, 2022 - 6 minutesmins - By Kostas Vavitsas Share WhatsApp Twitter Linkedin Email
News and Trends 2 May 2017 Novartis Gains Access to Celyad’s allogenic CAR-T cell patents …such as genome editing or genetic engineering. While Novartis‘ lead T cell product CTL019 is an autologous CAR-T therapy, which involves engineering the patient’s own cells, the new agreement is… May 2, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email